Literature DB >> 11150721

Activation of the small GTP-binding protein Ras in the heart by hypertrophic agonists.

P H Sugden1, A Clerk.   

Abstract

The small (21-kDa) guanine nucleotide-binding protein Ras plays a central role in the regulation of cell growth and division. In the cardiac myocyte, it has been implicated in the hypertrophic adaptation. We have recently examined the ability of hypertrophic agonists such as endothelin-1, phenylephrine and phorbol esters to increase the "activity" (GTP loading) of Ras. We have also studied the signaling events that lead to activation of Ras and the processes that respond to Ras activation. In this brief review, we describe these studies and set them within the context of the hypertrophic response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11150721     DOI: 10.1016/s1050-1738(00)00038-4

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  10 in total

Review 1.  Mitochondrial sirtuins in the heart.

Authors:  Heiko Bugger; Constantin N Witt; Christoph Bode
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

2.  Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice.

Authors:  Nicoletta Potenza; Carmine Vecchione; Antonella Notte; Assunta De Rienzo; Annamaria Rosica; Lisa Bauer; Andrea Affuso; Mario De Felice; Tommaso Russo; Roberta Poulet; Giuseppe Cifelli; Gabriella De Vita; Giuseppe Lembo; Roberto Di Lauro
Journal:  EMBO Rep       Date:  2005-05       Impact factor: 8.807

3.  Capacity for resolution of Ras-MAPK-initiated early pathogenic myocardial hypertrophy modeled in mice.

Authors:  Bih-Rong Wei; Philip L Martin; Shelley B Hoover; Elizabeth Spehalski; Mia Kumar; Mark J Hoenerhoff; Julian Rozenberg; Charles Vinson; R Mark Simpson
Journal:  Comp Med       Date:  2011-04       Impact factor: 0.982

4.  Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).

Authors:  Mark Rolfe; Laura E McLeod; Phillip F Pratt; Christopher G Proud
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

5.  A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling.

Authors:  Raghu S Nagalingam; Nagalingam R Sundaresan; Mahesh P Gupta; David L Geenen; R John Solaro; Madhu Gupta
Journal:  J Biol Chem       Date:  2013-02-27       Impact factor: 5.157

6.  Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.

Authors:  Junwang Xu; Fraz A Ismat; Tao Wang; Min Min Lu; Nicole Antonucci; Jonathan A Epstein
Journal:  Circ Res       Date:  2009-07-02       Impact factor: 17.367

7.  Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice.

Authors:  Nagalingam R Sundaresan; Madhu Gupta; Gene Kim; Senthilkumar B Rajamohan; Ayman Isbatan; Mahesh P Gupta
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

8.  Electroacupuncture at PC6 (Neiguan) Improves Extracellular Signal-Regulated Kinase Signaling Pathways Through the Regulation of Neuroendocrine Cytokines in Myocardial Hypertrophic Rats.

Authors:  Jia Li; Jing Li; Fengxia Liang; Yaqun Hong; Song Wu; Hongtu Tang; Hua Wang
Journal:  Evid Based Complement Alternat Med       Date:  2011-08-24       Impact factor: 2.629

9.  Gastrodin Exerts Cardioprotective Action via Inhibition of Insulin-Like Growth Factor Type 2/Insulin-Like Growth Factor Type 2 Receptor Expression in Cardiac Hypertrophy.

Authors:  Jun Lu; Xin Ma; Wen-Cong Gao; Xin Zhang; Yuanling Fu; Qian Liu; Lixiang Tian; Xiao-Dan Qin; Weimin Yang; Hong-Yi Zheng; Chang-Bo Zheng
Journal:  ACS Omega       Date:  2021-06-21

10.  Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity.

Authors:  Hongbing Xiao; Xiong Qin; Ding Ping; Keqiang Zuo
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.